Evidence map›Paper›PMID 27446798›Full record

ReviewFrontiers in oncology2016

The Expanding Toolbox of In Vivo Bioluminescent Imaging.

Tingting Xu, Dan Close, Winode Handagama, Enolia Marr, Gary Sayler, Steven Ripp

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Review
  2. Article
  3. Non-invasiveSurgery open science · 2026
    Article
  4. Review
  5. Article
  6. OptimizediScience · 2024
    Article
  7. Exploring the Light-Emitting Agents inJournal of the American Chemical Society · 2024
    Article
  8. Review
  9. The Role of Optical Imaging in Translational Nanomedicine.Journal of functional biomaterials · 2022
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Using Biosensors to Study Protein-Protein Interaction in the Hippo Pathway.Frontiers in cell and developmental biology · 2021
    Review
  19. Live Imaging.Current issues in molecular biology · 2021
    Review
  20. A Photocleavable Contrast Agent for Light-Responsive MRI.Pharmaceuticals (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tingting XuThe Center for Environmental Biotechnology, The University of Tennessee , Knoxville, TN , USA.
Dan Close490 BioTech, Inc. , Knoxville, TN , USA.
Winode HandagamaThe Department of Biology, Maryville College , Maryville, TN , USA.
Enolia MarrThe Center for Environmental Biotechnology, The University of Tennessee , Knoxville, TN , USA.
Gary SaylerThe Center for Environmental Biotechnology, The University of Tennessee, Knoxville, TN, USA; 490 BioTech, Inc., Knoxville, TN, USA.
Steven RippThe Center for Environmental Biotechnology, The University of Tennessee, Knoxville, TN, USA; 490 BioTech, Inc., Knoxville, TN, USA.

Funding

Development of a high-throughput screen to detect the effects of both pre- and post-biotransformed compounds for enhanced content drug discovery workflowsR44GM112241 · NIGMS · 490 BIOTECH, INC. · PI SAYLER, GARY S · 2017 to 2018
$997k
Expressing bacterial bioluminescence in human cell lines: Engineering autobioluminescent reporter cells to screen for endocrine disruptor chemicalsR44ES022567 · NIEHS · 490 BIOTECH, INC. · PI MORRISON, DAN · 2015 to 2016
$996k
Expressing humanized bacterial luciferase in stem cells: Moving beyond fireflyluciferase to expand the informational capacity of animal models for regenerativemedicineR42GM116622 · NIGMS · 490 BIOTECH, INC. · PI MORRISON, DAN · 2017 to 2018
$994k
From luc to GFP to lux: Evolving an improved zebrafish model for the screening ofR15ES023979 · NIEHS · UNIVERSITY OF TENNESSEE KNOXVILLE · PI RIPP, STEVEN A · 2014 to 2015
$379k
Expressing humanized bacterial luciferase in stem cells: Moving beyond firefly luciferase to expand the informational capacity of animal models for regenerative medicineR41GM116622 · NIGMS · 490 BIOTECH, INC. · PI MORRISON, DAN · 2015 to 2015
$150k
Development of a high-throughput screen to detect the effects of both pre- and post-biotransformed compounds for enhanced content drug discovery workflowsR43GM112241 · NIGMS · 490 BIOTECH, INC. · PI SAYLER, GARY S · 2015 to 2015
$149k
Expressing bacterial bioluminescence in human cell lines: Engineering autobiolumiR43ES022567 · NIEHS · 490 BIOTECH, INC. · PI MORRISON, DAN · 2013 to 2013
$138k
NIEHS NIH HHS R15 ES023979NIEHS NIH HHS R43 ES022567NIEHS NIH HHS R44 ES022567NIGMS NIH HHS R41 GM116622NIGMS NIH HHS R42 GM116622NIGMS NIH HHS R43 GM112241NIGMS NIH HHS R44 GM112241
6 · The paper itself

Abstract

In vivo bioluminescent imaging (BLI) permits the visualization of engineered bioluminescence from living cells and tissues to provide a unique perspective toward the understanding of biological processes as they occur within the framework of an authentic in vivo environment. The toolbox of in vivo BLI includes an inventory of luciferase compounds capable of generating bioluminescent light signals along with sophisticated and powerful instrumentation designed to detect and quantify these light signals non-invasively as they emit from the living subject. The information acquired reveals the dynamics of a wide range of biological functions that play key roles in the physiological and pathological control of disease and its therapeutic management. This mini review provides an overview of the tools and applications central to the evolution of in vivo BLI as a core technology in the preclinical imaging disciplines.

Indexed as

bioluminescencein vivo imagingluciferaseluciferinoptical imaging

Identifiers

PMID27446798
PMCPMC4917529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.